Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity

Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity

Authors: Yan Wang, Haiqing Ni, Shuaixiang Zhou, Kaijie He, Yarong Gao, Weiwei Wu, Min Wu, Zhihai Wu, Xuan Qiu, Ying Zhou, Bingliang Chen, Donghui Pan, Chenrong Huang, Mingzhu Li, Yicong Bian, Min Yang, Liyan Miao & Junjian Liu

Citation: Wang, Y., Ni, H., Zhou, S. et al. Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity. Cancer Immunol Immunother. (2021). https://doi.org/10.1007/s00262-020-02679-5

Used in this study: humanized B-hCD47 mice

Read entire article

Share:

Back to top